

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's 0 290-0050 020	or agent's file reference	FOR FURTHER ACTION		T/ISA/220) as well as, where applicable, item 5			
International PCT/US03/1	application No. 7577	International filing date (day/ma) 04 June 2003 (04.06.2003)		(Earliest) Priority Date (day/month/year) 04 June 2002 (04.06.2002)			
Applicant PURDUE RESEARCH FOUNDATION							
		n prepared by this International opy is being transmitted to the It		Authority and is transmitted to the Bureau.			
This interna	tional search report consists It is also accompanie	s of a total of $\underline{4}$ sheets. d by a copy of each prior art do	cument cite	d in this report.			
a. V		the international search was carri l, unless otherwise indicated unde		ne basis of the international application in the			
	the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international earch was carried out on the basis of the sequence listing:						
	contained in the internation	al application in written form.					
	filed together with the inter	national application in computer	readable for	m.			
	furnished subsequently to the	his Authority in written form.					
	furnished subsequently to this Authority in computer readable form.						
	the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.						
	the statement that the infor- been furnished.	mation recorded in computer read	iable form is	s identical to the written sequence listing has			
2.	Certain claims were found	d unsearchable (See Box I).					
3	Unity of invention is lacki	ing (See Box II).					
4. With r	egard to the title,	missad hu sha amaliaans					
	the text is approved as sub-	• ••	loumi				
	the text has occur established	ed by this Authority to read as fol	iows:				
5. With r	egard to the abstract,						
4\	the text is approved as sub	mitted by the applicant.					
	• • •	• ••	this Author	ity as it appears in Box III. The applicant			
				arch report, submit comments to this			
6. The figure of the drawings to be published with the abstract is Figure No.							
	as suggested by the applica	ant.		None of the figures			
	because the applicant faile	d to suggest a figure.					
	because this figure better	characterizes the invention.					

Form PCT/ISA/210 (first sheet) (July 1998)



International	application	No.

PCT/US03/17577

	2000					
A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 39/12 US CL : 424/199.1						
	International Patent Classification (IPC) or to both na	ational classification and IPC				
	DS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/185.1, 199.1, 207.1; 435/320.1; 536/23.4, 23.72						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet						
	UMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where ap		Relevant to claim No.			
Х	WO 01/83730 A2 (KOBINGER et al.) 08 November	r 2001 (08.11.2001) see claims.	1, 3-9, 13, 14, 17-25			
A			2, 10-12, 15, 16			
x	KOBINGER et al. Filovirus-pseudotyped lentiviral	vector can efficiently and stably	1, 3-9, 13, 14, 17-25			
	transduce airway epithelia in vivo. Nature Biotechn					
A	pages 225-230.		2, 10-12, 15, 16			
Y	WATSON et al. Targeted transduction patterns in the	ne mouse brain by lentivirus vectors	1-9, 13-14, 17-25			
	pseudotyped with VSV, Ebola, Mokola, LCMV, or					
A	Therapy. May 2002, Vol. 5, No. 1, pages 528-537.		10-12, 15, 16			
X	JOHNSON et al. Pseudotyped human lentiviral vect epithelia in vivo. Gene Therapy. April 2000, Vol. 7	1, 3, 4, 7, 9, 14				
Y	cpicina in vivo. Gene Therapy. April 2000, voi. 7	, No. 7, pages 300-374.	2, 8, 13, 17-25			
<u></u>		· <u></u>				
Further	r documents are listed in the continuation of Box C.	See patent family annex.				
• s	pecial categories of cited documents:	"T" later document published after the in priority date and not in conflict with				
	it defining the general state of the art which is not considered to indicate relevance	understand the principle or theory u	nderlying the invention			
		"X" document of particular relevance; the considered novel or cannot be consisted when the document is taken alo	dered to involve an inventive			
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art				
"O" document referring to an oral disclosure, use, exhibition or other means						
"P" document published prior to the international filing date but later than the priority date claimed						
Date of the	actual completion of the international search	Date of mailing of the international search report				
	29 July 2004 (29.07.2004) Name and mailing address of the ISA/US Authorized officer					
Ma	ail Stop PCT, Attn: ISA/US ommissioner for Patents	Calevil Bell-Harrisfor				
P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. (571)-272-1600						
Facsimile No. (703) 872=9306						
NICTI-4306						

Form PCT/ISA/210 (second sheet) (July 1998)

PCT/US03/17577

INTERNATIONAL SEARCH REPORT

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT						
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
X, P	JEFFERS et al. Covalent modifications of the ebola virus glycoprotein. Journal of Virology. December 2002, Vol. 76, No. 24, pages 12463-12472.	1-3, 5-25				
Y, P	Viology: December 2002, Vol. 70, 100. 24, pages 12403-12472.	4				
Х, Р	SINN et al. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. Journal of Virology, May 2003, Vol. 77, No. 10, pages 5902-5910.	1, 3-10, 13, 14, 17- 25				
·		·				
	,					

Form PCT/ISA/210 (second sheet) (July 1998)

Form PCT/ISA/210 (second sheet) (July 1998)

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article," "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Preliminary Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When? Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- 1. [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- (Where originally there were 15 claims and after amendment of all claims there are 11): "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II.